Robyn Hunter - 10 Dec 2024 Form 4 Insider Report for TENAX THERAPEUTICS, INC. (TENX)

Role
Director
Signature
/s/ S. Halle Vakani, as Attorney-in-Fact
Issuer symbol
TENX
Transactions as of
10 Dec 2024
Net transactions value
$0
Form type
4
Filing time
12 Dec 2024, 20:04:13 UTC
Previous filing
10 Jun 2022
Next filing
03 Jul 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TENX Stock Option (right to buy) Award $0 +100,000 $0.000000 100,000 10 Dec 2024 Common Stock 100,000 $5.94 Direct
holding TENX Stock Option (right to buy) 4 10 Dec 2024 Common Stock 4 $992.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These options were previously reported as covering 6,250 shares at an exercise price of $0.62 per share, but were adjusted to reflect the stock splits that occurred on January 4, 2023 and January 2, 2024.